Tamarack Advisers’s Rigel Pharmaceuticals RIGL Stock Holding History

Tamarack Advisers’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-125,000	Closed	-$1.61M	–	32
2023 Q2	$1.61M	Sell	125,000 -75,000	-38%	-$1.01M	0.5%	25
2023 Q1	$2.64M	Sell	200,000 -30,000	-13%	-$477K	0.96%	21
2022 Q4	$3.45M	Buy	230,000 +30,000	+15%	+$275K	1.78%	19
2022 Q3	$2.36M	Hold	200,000	–	–	1.39%	23
2022 Q2	$2.26M	Sell	200,000 -125,000	-38%	-$2.51M	1.31%	22
2022 Q1	$9.72M	Sell	325,000 -125,000	-28%	-$3.38M	4.6%	7
2021 Q4	$11.9M	Sell	450,000 -250,000	-36%	-$7.54M	4.9%	6
2021 Q3	$25.4M	Buy	700,000 +60,000	+9%	+$2.36M	8.02%	2
2021 Q2	$27.8M	Sell	640,000 -195,000	-23%	-$7.36M	7.87%	2
2021 Q1	$28.6M	Buy	835,000 +90,000	+12%	+$3.56M	5.86%	3
2020 Q4	$26M	Sell	745,000 -5,000	-0.7%	-$145K	5.41%	4
2020 Q3	$18M	Buy	750,000 +65,000	+9%	+$1.6M	5.55%	5
2020 Q2	$12.5M	Buy	685,000 +130,000	+23%	+$2.34M	3.49%	11
2020 Q1	$8.66M	Sell	555,000 -20,000	-3%	-$426K	3.28%	12
2019 Q4	$11.8M	Buy	575,000 +27,500	+5%	+$566K	2.69%	18
2019 Q3	$10.2M	Hold	547,500	–	–	2.67%	12
2019 Q2	$14M	Buy	547,500 +17,500	+3%	+$395K	4.26%	10
2019 Q1	$13.6M	Sell	530,000 -20,000	-4%	-$457K	5.41%	7
2018 Q4	$12.7M	Buy	550,000 +95,000	+21%	+$2.68M	5.16%	10
2018 Q3	$14.6M	Buy	455,000 +192,500	+73%	+$5.78M	4.17%	9
2018 Q2	$7.43M	Buy	+262,500	New	+$9.34M	2.49%	15

Other funds holding RIGL

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Tamarack Advisers's RIGL Position: Q3 2023 in Review

Tamarack Advisers sold out of Rigel Pharmaceuticals (RIGL) in Q3 2023, closing a stake of 125,000 shares — an estimated $1.61M sold.

Tamarack Advisers first reported a position in RIGL in Q2 2018 and held it in 21 quarters. The position peaked at $28.6M in Q1 2021. 106 funds tracked by Wall St. Rank hold RIGL as of Q3 2023.

Tamarack Advisers reported no remaining Rigel Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Tamarack Advisers sold 125,000 Rigel Pharmaceuticals shares in Q3 2023, an estimated $1.61M.
Tamarack Advisers first reported a position in Rigel Pharmaceuticals in Q2 2018 and held it in 21 quarters.
Tamarack Advisers's Rigel Pharmaceuticals position peaked at $28.6M in Q1 2021.
106 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2023.

Based on Tamarack Advisers's 13F filing for Q3 2023, filed 16 Nov 2023.